Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.38 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863386 | 0.95 | PTPN1 (0.40) | SMN1; SMN2ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL2869316 | 0.87 | NPSR1 (0.35) | SMN1; SMN2KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2863081 | 0.87 | KDM4E (0.43) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2863335 | 0.87 | TNKS (0.46) | SMN1; SMN2KDM4EMEN1KMT2AGAA | |
| SCHEMBL2862573 | 0.83 | HCRTR2 (0.41) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2861976 | 0.82 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2867440 | 0.82 | EP300 (0.42) | GAA | |
| SCHEMBL2866128 | 0.80 | STING1 (0.38) | SMN1; SMN2MEN1KMT2AGAAHTT | |
| Hydrochloric Acid SCHEMBL2867899 | 0.80 | AKT1 (0.36) | HDAC6 | |
| SCHEMBL2861932 | 0.80 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | SMN1; SMN2 4533/4885ALDH1A1 2926/4885KDM4E 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.